FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912405998> ?p ?o ?g. }

• W2912405998 endingPage "28" @default.
• W2912405998 startingPage "22" @default.
• W2912405998 abstract "Background This multicenter, double-blind phase II study assessed the antitumor activity and toxicity profile of docetaxel with the antiangiogenic multikinase inhibitor sorafenib or matching placebo as a first-line treatment in patients with metastatic or locally advanced HER2-negative breast cancer. Patients and methods Patients were randomized 1:1 to receive docetaxel 100 mg/m2 on day 1 every 3 weeks in combination with sorafenib 400 mg bid or placebo on days 2–18 of each cycle until tumor progression, or unacceptable toxicity. Sorafenib/placebo could be continued at the investigator's discretion if docetaxel was stopped due to toxicity. Primary endpoint was progression free survival (PFS). Results From October 2008 to December 2013, 102 patients were randomized; 98 patients were evaluable. The trial was prematurely terminated due to slow accrual. Due to increased toxicity the dose of docetaxel was reduced to 75 mg/m2 and an increasing sorafenib dosing schedule was implemented as part of a protocol amendment. The addition of sorafenib to docetaxel did not improve PFS (8.2 vs. 7.3 months for docetaxel/placebo; HR 0.84, log rank p = 0.43), but led to higher rates of early treatment discontinuation. There were no statistically significant differences between sorafenib dosing schedules. Conclusions Addition of sorafenib to taxane-based first-line chemotherapy in patients with metastatic breast cancer failed to improve PFS and resulted in increased toxicity." @default.
• W2912405998 created "2019-02-21" @default.
• W2912405998 creator A5000708354 @default.
• W2912405998 creator A5010774833 @default.
• W2912405998 creator A5011232197 @default.
• W2912405998 creator A5013148496 @default.
• W2912405998 creator A5017728105 @default.
• W2912405998 creator A5018436714 @default.
• W2912405998 creator A5020371513 @default.
• W2912405998 creator A5027522379 @default.
• W2912405998 creator A5036531617 @default.
• W2912405998 creator A5056688392 @default.
• W2912405998 creator A5059885667 @default.
• W2912405998 creator A5069413058 @default.
• W2912405998 creator A5085546495 @default.
• W2912405998 creator A5089392438 @default.
• W2912405998 creator A5089479249 @default.
• W2912405998 date "2019-06-01" @default.
• W2912405998 modified "2023-10-02" @default.
• W2912405998 title "Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study" @default.
• W2912405998 cites W1997961380 @default.
• W2912405998 cites W2003999835 @default.
• W2912405998 cites W2029088092 @default.
• W2912405998 cites W2029197596 @default.
• W2912405998 cites W2029641253 @default.
• W2912405998 cites W2061345986 @default.
• W2912405998 cites W2068014745 @default.
• W2912405998 cites W2085529853 @default.
• W2912405998 cites W2099824657 @default.
• W2912405998 cites W2100661360 @default.
• W2912405998 cites W2103563357 @default.
• W2912405998 cites W2103979740 @default.
• W2912405998 cites W2109800555 @default.
• W2912405998 cites W2111879300 @default.
• W2912405998 cites W2114159573 @default.
• W2912405998 cites W2126275851 @default.
• W2912405998 cites W2131528383 @default.
• W2912405998 cites W2153982924 @default.
• W2912405998 cites W2167224460 @default.
• W2912405998 cites W2254355127 @default.
• W2912405998 cites W2286465291 @default.
• W2912405998 cites W2350984935 @default.
• W2912405998 cites W2406454314 @default.
• W2912405998 cites W2547100318 @default.
• W2912405998 doi "https://doi.org/10.1016/j.breast.2019.02.002" @default.
• W2912405998 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30822621" @default.
• W2912405998 hasPublicationYear "2019" @default.
• W2912405998 type Work @default.
• W2912405998 sameAs 2912405998 @default.
• W2912405998 citedByCount "9" @default.
• W2912405998 countsByYear W29124059982021 @default.
• W2912405998 countsByYear W29124059982022 @default.
• W2912405998 countsByYear W29124059982023 @default.
• W2912405998 crossrefType "journal-article" @default.
• W2912405998 hasAuthorship W2912405998A5000708354 @default.
• W2912405998 hasAuthorship W2912405998A5010774833 @default.
• W2912405998 hasAuthorship W2912405998A5011232197 @default.
• W2912405998 hasAuthorship W2912405998A5013148496 @default.
• W2912405998 hasAuthorship W2912405998A5017728105 @default.
• W2912405998 hasAuthorship W2912405998A5018436714 @default.
• W2912405998 hasAuthorship W2912405998A5020371513 @default.
• W2912405998 hasAuthorship W2912405998A5027522379 @default.
• W2912405998 hasAuthorship W2912405998A5036531617 @default.
• W2912405998 hasAuthorship W2912405998A5056688392 @default.
• W2912405998 hasAuthorship W2912405998A5059885667 @default.
• W2912405998 hasAuthorship W2912405998A5069413058 @default.
• W2912405998 hasAuthorship W2912405998A5085546495 @default.
• W2912405998 hasAuthorship W2912405998A5089392438 @default.
• W2912405998 hasAuthorship W2912405998A5089479249 @default.
• W2912405998 hasConcept C121608353 @default.
• W2912405998 hasConcept C126322002 @default.
• W2912405998 hasConcept C142724271 @default.
• W2912405998 hasConcept C143998085 @default.
• W2912405998 hasConcept C168563851 @default.
• W2912405998 hasConcept C203092338 @default.
• W2912405998 hasConcept C204787440 @default.
• W2912405998 hasConcept C27081682 @default.
• W2912405998 hasConcept C2775930923 @default.
• W2912405998 hasConcept C2776694085 @default.
• W2912405998 hasConcept C2777511904 @default.
• W2912405998 hasConcept C2778019345 @default.
• W2912405998 hasConcept C2778695046 @default.
• W2912405998 hasConcept C2778715236 @default.
• W2912405998 hasConcept C2781190966 @default.
• W2912405998 hasConcept C29730261 @default.
• W2912405998 hasConcept C530470458 @default.
• W2912405998 hasConcept C71924100 @default.
• W2912405998 hasConceptScore W2912405998C121608353 @default.
• W2912405998 hasConceptScore W2912405998C126322002 @default.
• W2912405998 hasConceptScore W2912405998C142724271 @default.
• W2912405998 hasConceptScore W2912405998C143998085 @default.
• W2912405998 hasConceptScore W2912405998C168563851 @default.
• W2912405998 hasConceptScore W2912405998C203092338 @default.
• W2912405998 hasConceptScore W2912405998C204787440 @default.
• W2912405998 hasConceptScore W2912405998C27081682 @default.
• W2912405998 hasConceptScore W2912405998C2775930923 @default.
• W2912405998 hasConceptScore W2912405998C2776694085 @default.
• W2912405998 hasConceptScore W2912405998C2777511904 @default.

• next